Phase II trial of PALA in combination with 5-fluorouracil in advanced pancreatic cancer

Elizabeth Rosyold; Russell J. Schilder; Judy Walczak; Santo M. DiFino; Patrick J. Flynn; T. K. Banerjee; W. Heim; P. Engstrom; Robert F. Ozols; Peter J. O’Dwyer

doi:10.1007/bf00685949

Keywords

FluorouracilMedicinePancreatic cancerDiarrheaToxicityChemotherapyGastroenterologyAntimetaboliteInternal medicineColorectal cancerNeurotoxicityPhases of clinical researchCancerPharmacologyOncology

Affiliated Institutions

Related Publications

Phase III Study of Docetaxel and Cisplatin Plus Fluorouracil Compared With Cisplatin and Fluorouracil As First-Line Therapy for Advanced Gastric Cancer: A Report of the V325 Study Group

Eric Van Cutsem , Vladimir Moiseyenko , Sergei Tjulandin +9 more

Purpose In the randomized, multinational phase II/III trial (V325) of untreated advanced gastric cancer patients, the phase II part selected docetaxel, cisplatin, and fluorourac...

2006 Journal of Clinical Oncology 1912 citations

Therapeutic Synergy Between Irinotecan and 5-Fluorouracil against Human Tumor Xenografts

Rami G. Azrak , Shousong Cao , Harry K. Slocum +7 more

Abstract Purpose: Although the combination of irinotecan and 5-Fluorouracil is clinically active, it is associated with significant toxicity and resistance. Studies were carried...

2004 Clinical Cancer Research 100 citations

Randomized Phase III Study of Exatecan and Gemcitabine Compared With Gemcitabine Alone in Untreated Advanced Pancreatic Cancer

Ghassan K. Abou‐Alfa , Richard Létourneau , Graydon Harker +8 more

Purpose Exatecan mesylate is a hexacyclic, water-soluble, topoisomerase-1 inhibitor. Exatecan has single-agent and combination activity with gemcitabine in advanced pancreatic c...

2006 Journal of Clinical Oncology 277 citations

Specific <i>EGFR</i> Mutations Predict Treatment Outcome of Stage IIIB/IV Patients With Chemotherapy-Naive Non–Small-Cell Lung Cancer Receiving First-Line Gefitinib Monotherapy

James Chih‐Hsin Yang , Chong‐Jen Yu , Jin‐Yuan Shih +12 more

Purpose To explore predictive factors for time to treatment failure (TTF) in chemotherapy-naive non–small-cell lung cancer (NSCLC) patients receiving gefitinib treatment. Patien...

2008 Journal of Clinical Oncology 240 citations

Irinotecan Plus Oxaliplatin and Leucovorin-Modulated Fluorouracil in Advanced Pancreatic Cancer—A Groupe Tumeurs Digestives of the Fédération Nationale des Centres de Lutte Contre le Cancer Study

Thierry Conroy , B Paillot , Éric François +10 more

Purpose To evaluate response rate and toxicity of irinotecan and oxaliplatin plus fluorouracil (FU) and leucovorin (Folfirinox) in advanced pancreatic adenocarcinoma (APA). Pati...

2005 Journal of Clinical Oncology 238 citations

Publication Info

Year: 1992
Type: article
Volume: 29
Issue: 4
Pages: 305-308
Citations: 24
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

Phase II trial of PALA in combination with 5-fluorouracil in advanced pancreatic cancer

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

OpenAlex

Cite This

APA Style

                            
                                
                                    Elizabeth Rosyold, 
                                
                                    Russell J. Schilder, 
                                
                                    Judy Walczak
                                
                                et al.
                            
                            (1992). 
                            Phase II trial of PALA in combination with 5-fluorouracil in advanced pancreatic cancer. 
                            Cancer Chemotherapy and Pharmacology
                            , 29
                            (4)
                            , 305-308.
                            https://doi.org/10.1007/bf00685949
                        

Identifiers

DOI: 10.1007/bf00685949